Published in Z Rheumatol on December 01, 2013
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum (2012) 1.66
Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis (2011) 1.53
Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. Rheumatol Int (2002) 1.33
Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum (2009) 1.21
[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]. Z Rheumatol (2006) 1.18
Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol (1996) 1.10
ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version. Ann Rheum Dis (2008) 1.09
The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis--a randomized controlled trial. J Rheumatol (1990) 1.05
[German patient version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis]. Z Rheumatol (2010) 0.99
Relationship between smoking and patient-reported measures of disease outcome in ankylosing spondylitis. J Rheumatol (2011) 0.98
Home-based exercise therapy in patients with ankylosing spondylitis: effects on pain, mobility, disease activity, quality of life, and respiratory functions. Clin Rheumatol (2011) 0.95
Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. Rheumatol Int (2004) 0.94
Effects of a home-based exercise program on quality of life, fatigue, and depression in patients with ankylosing spondylitis. Rheumatol Int (2008) 0.93
[Advice for patients diagnosed with ankylosing spondylitis: results of a representative patient survey in Germany]. Z Rheumatol (2011) 0.81
[Ankylosing Spondylitis and convenient nutrition]. Wien Med Wochenschr (2008) 0.81
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum (1998) 6.16
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum (2003) 2.78
Ankylosing spondylitis: an overview. Ann Rheum Dis (2002) 2.71
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis (2013) 2.32
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis (2006) 1.94
Association of genotypes affecting the expression of interleukin-1beta or interleukin-1 receptor antagonist with osteoarthritis. Arthritis Rheum (2000) 1.88
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis (2004) 1.56
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis (2005) 1.51
Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis (2004) 1.49
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis (2011) 1.46
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis (2007) 1.43
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) (2004) 1.37
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis (2005) 1.37
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum (2010) 1.33
Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis (2004) 1.33
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum (2007) 1.28
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum (2005) 1.25
Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis (2011) 1.21
[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]. Z Rheumatol (2006) 1.18
Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis (2011) 1.18
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) (2007) 1.18
Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) (2005) 1.15
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis (2007) 1.15
Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis (2005) 1.14
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis (2004) 1.14
[Diagnosis of reactive arthritis]. Z Rheumatol (2004) 1.13
Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum (1999) 1.09
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Ann Rheum Dis (2005) 1.09
Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum (2009) 1.04
An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis (2006) 1.02
Whole-body MRI as a new screening tool for detecting axial and peripheral manifestations of spondyloarthritis. Ann Rheum Dis (2007) 1.01
The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis (2008) 1.00
Increased frequency of Sjögren's syndrome in patients with spondyloarthropathy. J Rheumatol (1998) 0.98
Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) (1999) 0.97
Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford) (2003) 0.96
[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]. Z Rheumatol (2003) 0.96
Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis (2003) 0.93
Interethnic studies of TNF polymorphisms confirm the likely presence of a second MHC susceptibility locus in ankylosing spondylitis. Genes Immun (2000) 0.92
Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis (2004) 0.91
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis (2013) 0.91
Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis (2008) 0.91
Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis (2013) 0.90
Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum (2008) 0.88
Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences. Ann Rheum Dis (2000) 0.88
Treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Oxford) (2003) 0.87
Easy assessment of axial spondyloarthritis (early ankylosing spondylitis) at the bedside. Ann Rheum Dis (2006) 0.86
[Outcome parameters in ankylosing spondylitis]. Z Rheumatol (2006) 0.85
Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis (2010) 0.83
Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis (2013) 0.83
Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann Rheum Dis (2004) 0.83
[Imaging in ankylosing spondylitis]. Z Rheumatol (2007) 0.82
[Advice for patients diagnosed with ankylosing spondylitis: results of a representative patient survey in Germany]. Z Rheumatol (2011) 0.81
Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol (2015) 0.81
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 4 Classification and diagnostic criteria]. Z Rheumatol (2014) 0.81
Performances of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter, cross-sectional study. Arthritis Care Res (Hoboken) (2013) 0.80
[Early axial spondyloarthritis. Diagnostic approach and screening]. Z Rheumatol (2012) 0.79
Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjögren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis. Clin Exp Rheumatol (2002) 0.79
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 1 Introduction/preliminary comments]. Z Rheumatol (2014) 0.79
["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]. Dtsch Med Wochenschr (2009) 0.78
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 6 Diagnostics]. Z Rheumatol (2014) 0.78
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms]. Z Rheumatol (2014) 0.77
Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin. Rheumatology (Oxford) (2002) 0.77
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]. Z Rheumatol (2014) 0.77
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8 Therapy, 8.1 Treatment concept, 8.2 Therapy targets and strategy]. Z Rheumatol (2014) 0.77
T cell response to human HSP60 and yersinia 19 kDa in ankylosing spondylitis and rheumatoid arthritis: no evidence for a causal role of these antigens in the pathogenesis. Ann Rheum Dis (2002) 0.77
The role of germline polymorphisms in the T-cell receptor in susceptibility to ankylosing spondylitis. Br J Rheumatol (1998) 0.77
CD27+ memory and CD27- effector CD8+ T cells are responsible for a decreased production of proinflammatory cytokines in HLA B27-positive subjects. Clin Exp Rheumatol (2006) 0.77
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 5 Initial diagnosis/referral strategy]. Z Rheumatol (2014) 0.77
[Epidemiology and patient management in the area of spondyloarthritis]. Z Rheumatol (2002) 0.76
Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice. Clin Exp Rheumatol (2008) 0.76
[Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12]. Z Rheumatol (2004) 0.75
Positive and negative predictive values from published studies can be misleading for decision-making in clinical practice. Rheumatology (Oxford) (2006) 0.75
HLA associations of systemic lupus erythematosus in Chinese from Singapore. Ann Rheum Dis (1995) 0.75
[Fever of unknown origin in the 21st century. 2. Non-infectious diseases (autoimmune diseases)]. Dtsch Med Wochenschr (2005) 0.75
Synovial T cell proliferation to the Yersinia enterocolitica 19 kDa antigen differentiates yersinia triggered reactive arthritis (ReA) from ReA triggered by other enterobacteria. Ann Rheum Dis (2002) 0.75
[Imaging methods in rheumatology: imaging in psoriasis arthritis (PsA)]. Z Rheumatol (2006) 0.75
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 2 Preamble]. Z Rheumatol (2014) 0.75
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 7 Disease activity and prognosis of spondyloarthritis]. Z Rheumatol (2014) 0.75
[Spondyloarthritides]. Internist (Berl) (2011) 0.75
[New aspects in the area of spondyloarthritis. Report on the 6(th) International Congress on Spondyloarthropathies]. Z Rheumatol (2009) 0.75
Computational analysis of blood volume curves and risk of intradialytic morbid events in hemodialysis. Kidney Int (2000) 0.75
Polyurethan-coated lumen surface of Shaldon catheters is not damaged by heparin. Int J Artif Organs (1993) 0.75
[Fever of unknown origin in the 21st century: infectious diseases]. Dtsch Med Wochenschr (2005) 0.75